Monash copper ionophore ATH434 clears 52% of amyloid plaques in APP/PS1 mice at 12 weeks

The Monash study administered ATH434 at 30 mg/kg for 12 weeks. Treated mice showed decreased phospho-tau, restored synaptic markers, and normalized copper distribution measured by laser ablation ICP-MS. No weight loss or liver enzyme elevation occurred at the effective dose. Prior metal chelators such as PBT2 reached Phase II but failed primary endpoints in 2014 trials due to inconsistent brain copper delivery. ATH434 uses a distinct ionophore mechanism that increases intracellular copper without systemic depletion. This addresses documented failures in antibody programs where ARIA rates reached 36% in lecanemab Phase III. Health-economic models project that a disease-modifying oral agent could reduce Australian dementia care costs by AUD 4.2 billion annually by 2040 if efficacy scales to humans. Next steps require IND-enabling toxicology and a Phase I safety study in healthy elderly volunteers before any patient dosing.